PegInterferon - Peregrine Pharmaceuticals Files Shelf Registration Statement

Peregrine Pharmaceuticals Files Shelf Registration Statement
International News Service, Australia - Mar 31, 2006... In February, Peregrine successfully completed enrollment in a Tarvacin Phase l clinical trial for the treatment of chronic hepatitis C virus infection ...

Novartis Announces in-licensing of Valopicitabine (NM283), a Novel ...
PharmaLive.com (press release), PA - Mar 29, 2006... synergistic with valopicitabine, and this combination could become the first oral combination therapy available for the treatment of chronic hepatitis C. ...

Novelos Therapeutics Files SPA with FDA for Phase 3 Development in ...
Genetic Engineering News, NY - Mar 8, 2006... antiviral activity. Novelos plans to initiate a US-based NOV-205 clinical trial for chronic hepatitis C by mid-2006. Both compounds ...

Human Genome Sciences Reports Positive Interim Results of Phase 2 ...
Yahoo! News (press release) - Mar 14, 2006... safety, tolerability and efficacy of Albuferon(TM) (albumin-interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C who failed ...

ViRexx Announces Collaboration with Defence Research and ...
CCNMatthews (press release), Canada - Mar 31, 2006... The Company is also conducting preclinical studies on Chimigen TM therapeutic vaccine candidates to treat chronic hepatitis C infections. ...

Novelos seeks permission to test hepatitis drug in US
Pharmaceutical Business Review - Mar 24, 2006Biotech firm Novelos Therapeutics has filed an investigational new drug application with the FDA for its experimental chronic hepatitis C treatment, NOV-205. ...

MIGENIX Reports Third Quarter Fiscal Year 2006 Results
MSN Money - Mar 8, 2006... development programs, with two phase II clinical outcomes expected this year in our MX-3253 program for the treatment of chronic hepatitis C virus infections ...